Trend Chart

Technical Analysis

REGN

Regeneron Pharmaceuticals, Inc.stock
$784.85-0.58%
Bullish +10.5Updated 2026-09-22
Signal historyStrong +BullishNeutralBearishStrong −

Chart patterns

Same window as the main chart. Hover a pattern below to highlight where it appears on the candle chart. Not part of the composite signal.

Pattern chart

Same window as main (6M, 126 sessions)

Patterns we scan(4 of 10)

  • Bullish Engulfingbullishcandle3 on chart

    Two bars: a green body that fully covers the prior red body.

  • Bearish Engulfingbearishcandle4 on chart

    Two bars: a red body that fully covers the prior green body.

  • Morning Starbullishcandle2 on chart

    Three bars: selloff, small pause, then a reclaim — classic bottoming idea.

  • Evening Starbearishcandle7 on chart

    Three bars: rally, small pause, then a give-back — classic topping idea.

Technical context

Evidence from the current daily chart — not a price target or recommendation.

Upward evidence

  • Support / Resistance · near support 783.16
  • Moving Averages · price above MA200, MA20 > MA50

Downward evidence

  • MACD (12/26/9) · below signal, hist −
  • OBV Divergence · price ↓ / OBV ↓ (confirms down)

Score change · 5 sessions

+7.1

Score change · 20 sessions

-9.4

Current band held

2 sessions

Nearest support

$783.16 · -0.22%

Nearest resistance

$816.41 · +4.02%

Relative strength

Return difference against the benchmark over the same daily sessions.

vs SPY

1M

-5.70%

3M

+26.67%

6M

-9.02%

vs XLV

1M

-2.51%

3M

+15.97%

6M

-8.43%

Daily Commentary

2026-07-22

REGN: Sentiment Shifts to Strong Bearish Posture

REGN closed at $651.18 today, reflecting a 3.56% decline that triggered a significant shift in its composite technical signal from strong-bullish to strong-bearish at -19.9/100. This move followed a session where the price crossed a detected support/resistance level, underscoring the current volatility in the stock. The volume category is currently the primary drag on the composite score, landing at -32.5/100 as price and On Balance Volume both trend downward. While the MACD (12/26/9) maintains a bullish lean with a positive histogram, the Parabolic SAR remains above the price, confirming the current bearish bias. The stock is now positioned below its 200-day moving average, further weakening the structural outlook.

The price is currently situated at $651.18, leaving it 2.1% below the nearest resistance level of $665.13, which has seen nine touches, and 4.3% above the nearest support at $623.37, which has been tested ten times. Despite the bearish price structure score of -60.0/100, momentum indicators remain largely neutral, with the RSI at 48.9 and Stochastic %K at 38.9. The Bollinger Band position at 47% further suggests the asset is not yet at an extreme boundary despite the recent sell-off. These technical readings describe the state of the price action and volume but do not provide insight into underlying fundamental catalysts or future performance. The neutral momentum scores suggest that while the trend is weakening, the selling pressure is not yet reflected in every indicator.

CategoryBandScore
TrendBearish-7.5/100
MomentumNeutral0.0/100
VolumeStrong Bearish-32.5/100
Price StructureStrong Bearish-60.0/100
Key IndicatorValue
Current Close$651.18
Resistance (9 touches)$665.13
Support (10 touches)$623.37
Relative Volume1.15x

The composite technical data for REGN highlights a clear divide between the bearish volume and price structure and the neutral momentum readings. The shift in the composite signal reflects the breakdown of recent support levels and the downward trend in volume metrics. The stock remains in a technical position where the distance to established resistance is narrower than the distance to the identified support.

Informational only — not investment advice.

Statistics

Open
$787.34
Prev Close
$789.45
Day Range
$779.65 – $794.73
52W High
$859.34
52W Low
$541.00
Volume
2.5M
Avg Vol (20d)
701.3K

Looking for a quick summary? REGN summary →

Trend Chart technical chart analysis for Regeneron Pharmaceuticals, Inc. (REGN).